Conservative treatment of ulnar nerve compression at the elbow: a systematic review

Key points

1. 01Splinting improved symptoms in 89% of cases (95% CI, 69-99%) across five pooled studies
2. 02Steroid/lidocaine injection improved symptoms in 54% of cases (95% CI, 41-67%) across six pooled studies
3. 03Education and activity modification also produced positive outcomes in all studies reporting them
4. 04Physical therapy (neurodynamic mobilization plus ultrasound) showed 100% improvement in one small series, but evidence is too limited to draw firm conclusions
5. 05Natural history and placebo effects cannot be ruled out due to the absence of proper control groups

How it was conducted

Design

Systematic review and meta-analysis following PRISMA recommendations

Databases searched

MEDLINE, Embase, and Cochrane CENTRAL; search conducted May 2020

Included studies

19 studies (12 level IV, 7 level III evidence); 16 high quality, 3 moderate quality by JBI criteria

Participants

682 patients (684 arms) with ulnar neuropathy at the elbow; mean age 48.7 years

Interventions covered

Steroid/lidocaine injection, splint devices, physical therapy, pulsed ultrasound, laser therapy, education, and activity modification

Primary outcome

Proportion of patients with symptom improvement; meta-analyses performed for injection and splint subgroups using random-effects models

What they found

• Splinting subgroup (5 studies): pooled improvement rate 89% (95% CI, 69-99%); I2 = 92% (95% CI, 84-96%); average treatment duration 18.7 months
• Injection subgroup (6 studies): pooled improvement rate 54% (95% CI, 41-67%); I2 = 59% (95% CI, 0-83%); average follow-up 4.3 months
• Neurodynamic mobilization plus ultrasound therapy: 100% improvement (n = 7) at 12-month follow-up (Oskay et al)
• Ultrasound or low-level laser therapy: 69% improvement (n = 32) at 3-month follow-up (Ozkan et al)
• Education and activity modification: improvement ranged from 35% (Beekman et al, n = 46 arms) to 82% (Omejec et al, n = 67 arms) to 74% (Nakamichi et al, n = 80 arms) to 40% (Padua et al, n = 30 arms)
• Seror (splint, n = 22) and Svernlov et al (splint, n = 51) each reported 100% improvement; Shah et al reported 88% improvement (n = 24)
• Hong et al found no supplementary effect of adding a steroid injection to splinting

Limitations

• No control groups in any included study, so natural disease course and placebo effects cannot be excluded
• Heterogeneity was high for both meta-analysis subgroups (I2 59% for injections, 92% for splints), limiting confidence in pooled estimates
• Wide variation in outcome measures, follow-up durations, patient severity, and treatment protocols across studies prevents direct comparison
• Dropouts likely represent treatment failures, meaning effectiveness rates may be overestimated in several studies

Why it matters

For patients

If you have cubital tunnel syndrome and are not ready for surgery or cannot have it, wearing an elbow splint at night is the most supported non-surgical option and is worth discussing with your doctor.

For clinicians

Elbow splinting is the preferred first-line conservative option over steroid injection given a higher pooled improvement rate; both are appropriate as surgery alternatives or bridges, but trials with control groups are needed before strong recommendations can be made.

For readers

This review pools the best available data on non-surgical care for cubital tunnel syndrome and finds it effective for most patients, though the underlying study quality is modest and placebo or natural-recovery effects have not been adequately separated out.